Table 2.
Demographics of patients with subacute cutaneous lupus erythematosus reported in the US FDA Adverse Event Reporting System database between 1 July 2013 and 30 June 2015
| Characteristic | Total (n = 220) | Associated with PPI (n = 120) | Associated with other drugs (n = 100) |
|---|---|---|---|
| Sexa | |||
| Male | 26 (11.8) | 9 (7.5) | 17 (17.0) |
| Female | 170 (77.3) | 97 (80.8) | 73 (73.0) |
| Missing | 24 (10.9) | 14 (11.7) | 10 (10.0) |
| Age (years) | |||
| <25 | 10 (4.5) | 10 (8.3) | 0 (0) |
| ≥25 and <50 | 50 (22.7) | 25 (20.8) | 25 (25.0) |
| ≥50 and <70 | 71 (32.3) | 44 (36.7) | 27 (27.0) |
| ≥70 and <86 | 56 (25.5) | 19 (15.8) | 37 (37.0) |
| Missing | 33 (15.0) | 22 (18.3) | 11 (11.0) |
| Mortality | 7 (3.2) | 5 (4.2) | 2 (2.0) |
Data are presented as n (%)
PPI proton pump inhibitor
aFisher’s exact test (PPI and ‘other drugs’ vs. ‘male’ and ‘female’: p = 0.0269 [one tailed])